Patent SG-11201804969P-A (SG)
Title: Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
Inventor: LIU YANG
IPC: A61K39/395
Filed: 2016-12-14
Abstract: HingeY 254T T253E 52.98A 33A Humanization Hinge .252Y S254T T256E ;293A E333A K334A (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/106372 Al 22 June 2017 (22.06.2017) WIPO I PCT 111111111111110111010101111101011111011101011011011011111111011111111111110111111 (51) International Patent Classification: A61K 39/00 (2006.01) C12P 21/08 (2006.01) A61K 39/395 (2006.01) C07K 16/00 (2006.01) (21) International Application Number: PCT/US2016/066698 (22) International Filing Date: 14 December 2016 (14.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/267,735 15 December 2015 (15.12.2015) US 62/309,169 16 March 2016 (16.03.2016) US 62/359,036 6 July 2016 (06.07.2016) US (71) Applicant: ONCOIMMUNE, INC. [US/US]; 12111 Parklawn Drive, Suites 107,109, and 111, Rockville, Mary- land 20852 (US). (72) Inventors; and (71) Applicants (for US only): LIU, Yang [US/US]; 502 E Street NE, Washington, District of Columbia 20002 (US). ZHENG, Pan [US/US]; 502 E Street NE, Washington, District of Columbia 20002 (US). DEVENPORT, Martin [GB/US]; 607 Gatestone Street, Gaithersburg, Maryland 20878 (US). — (74) Agents: GALANT, Ron et al.; Polsinelli PC, 161 N. Clark Street, Suite 4200, Chicago, Illinois 60601 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) - (54) Title: CHIMERIC AND HUMANIZED ANTI-HUMAN CTLA4 MONOCLONAL ANTIBODIES AND USES THEREOF W O 20 17 / 10637 2 Al Chimeric Humanized L3D10 L3D10 FIG. 1 (57) : This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 mo - lecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.